psychiatrist.com logo

Clinical and Cost Implications of
Treating Schizophrenia: Safety, Efficacy,
Relapse Prevention, and Patient Outcomes

 

Online InfoPack Materials

Multimedia InfoPack

An interactive online version of the InfoPack including animated graphics that bring the data to life

InfoPack PDF

A printer-friendly online version of the InfoPack just as it was printed

Source Materials Available Online

Faculty Presenters

  • John M. Kane, MD (Chair)
  • Chair and Professor of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York
  • Christoph U. Correll, MD
  • Professor of Psychiatry and Molecular Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead;
    Medical Director, Recognition and Prevention Program (RAP), The Zucker Hillside Hospital, Glen Oaks, New York

 

  • Philip D. Harvey, MD
  • Leonard M. Miller Professor of Psychiatry and Behavioral Sciences,
    University of Miami Miller School of Medicine, Miami, Florida
  • Mark Olfson, MD, MPH
  • Professor of Psychiatry, Columbia University Medical Center; Research Psychiatrist II,
    New York State Psychiatric Institute, New York, New York

 

 

Faculty Disclosure

Dr Kane has been a consultant for Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, and Roche; has received honoraria from Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, and Roche; has been on the speakers/advisory boards for Bristol-Myers Squibb, Genentech, and Otsuka; and has been a stock shareholder in MedAvante.

Dr Correll has been a consultant for Bristol-Myers Squibb, Eli Lilly, Gerson Lehrman Group, Intra-Cellular Therapies, Lundbeck, MedAvante, Pfizer, ProPhase, Otsuka, Sunovion, and Vanda; has received grant/research support from Bristol-Myers Squibb, Janssen, Johnson & Johnson, Novo Nordisk A/S, and Otsuka; has received honoraria from Medscape; has been on the speaker/advisory boards of Alexza, Bristol-Myers Squibb, Eli Lilly, Genentech, Intra-Cellular Therapies, Lundbeck, Merck, Otsuka, Roche, and Sunovion; and has been a data safety monitoring board member for Eli Lilly, Cephalon, Janssen, Lundbeck, Pfizer, Takeda, and Teva.

Dr Harvey is a consultant for AbbVie, Boehringer Ingelheim, EnVivo, Forest, Genentech, Otsuka, Sunovion, and Takeda.

Dr Olfson is an employee of Columbia University, New York State Institute, Research Foundation for Mental Hygiene and has received grant/research support from the Agency for Health Care Policy & Research, the American Foundation for Suicide Prevention, and the National Institutes of Health.

Acknowledgment

This InfoPack is based on a series of discussions by 4 experts on the treatment of schizophrenia held in December 2013 and January 2014. This evidence-based, peer-reviewed InfoPack was prepared by Healthcare Global Village, Inc. Financial support for the preparation and dissemination of this InfoPack was provided by Sunovion Pharmaceuticals, Inc. The authors acknowledge Nancy Groves, BA, MS, Healthcare Global Village, Inc, for editorial assistance in development of the manuscripts. The opinions expressed herein are those of the authors and do not necessarily reflect the views of Healthcare Global Village, Inc, the publisher, the American Society of Clinical Psychopharmacology, or the commercial supporter.

Review Process

The faculty for this InfoPack discussed the content in a series of peer-review planning teleconferences, the chair and faculty reviewed the InfoPack for accuracy, and a member of the Journal’s Editorial Board who is without conflict of interest reviewed the InfoPack to determine whether the material is evidence-based and objective.

Psychiatrist.com The Journal of Clinical Psychiatry The Primary Care Companion for CNS Disorders The CME Institute Neurology Knowledge Terms of Use Privacy Policy